Please login to the form below
influenza
This page shows the latest influenza news and features for those working in and with pharma, biotech and healthcare.
Gilead continues its exec clear-out, licenses antivirals from Novartis
agents to treat human rhinovirus, influenza and herpes viruses.
Latest news
-
Shingrix lifts GSK in Q1, but two more vaccines are culled
Synflorix follow-up and influenza vaccine fail to make the cut. GlaxoSmithKline has already shed around a third of its pipeline projects since CEO Emma Walmsley took over, and two more ... The two abandoned projects include a phase 2 strep pneumonia
-
CHMP backs Lynparza in breast cancer, Dupixent in asthma
GlaxoSmithKline’s Dectova (zanamivir) under exceptional circumstances for the treatment of complicated and potentially life-threatening influenza;. -
-
Moderna files record $500m IPO for RNA pipeline
as well as vaccines for viral infections such as respiratory syncytial virus (RSV), influenza, chikungunya and Zika.
-
Roche’s new flu pill Xofluza approved in US
The treatment has been approved for acute, uncomplicated influenza in people 12 years of age and older, and has been shown to be effective against a wide range of flu viruses, ... The drug is also to be studied in a phase 3 programme including paediatric
-
Encouraging data for Roche flu drug ahead of FDA decision
Trial looks at benefts in high risk groups. Roche has produced promising phase 3 data for its first-in-class influenza treatment in patients who are at a high risk for ... The drug is also to be studied in a phase 3 programme including paediatric
More from news
Approximately 15 fully matching, plus 182 partially matching documents found.
Latest Intelligence
-
Biotech profile: Tom Evans, CEO, Vaccitech.
What are the shortcomings of current influenza vaccines, and why are new products needed? ... The outcome measurement is to decrease the amount of laboratory-confirmed influenza illness.
-
Deal Watch February 2016
coli and influenza, and in toxicology applications. While Abbott already has a significant diagnostics presence with global sales in 2015 in this segment of $4.6bn, it forecasts that the acquisition
-
Another lost decade for research?
diseases that cause significant morbidity and mortality, such as influenza and malaria, but remain difficult to vaccinate against.
-
Pharma deals in June 2015
85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).
-
Wearables: the tangible product of the patient revolution
The opportunity is massive - in the public health arena, there exists the possibility that outbreaks of diseases such as Ebola or influenza could be seen and stopped before they become critical.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Germany's Ventaleon names biotech entrepeneur CEO
patients suffering from serious infections such as influenza to get better, faster.
-
Dr Michael Watson appointed as president of Valera
Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.
-
NDA Group appoints Bill Griffiths as general manager, UK
systems teams as well as a specialist influenza vaccines unit.
-
Takeda appoints head of vaccines development
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
-
MHRA chairman steps down
He was previously chair of the MHRA's Commission of Human Medicines and the Department of Health's Scientific Pandemic Influenza Committee.
More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Fake News is Bad for your Health
Epidemics of measles are occurring across Europe. Rates of vaccination for influenza, HPV, tetanus and polio have also declined.
-
To track disease, follow the money
The way that influenza spreads can be tracked by tools such as Flusurvey,(1) which produces rapidly-updated heatmaps of illness across the country.
-
Influenza
Agency: BASTARD. LONDON. Product: Self Promotion. Client: Self Promotion. Therapy area: Self Promotion. View the PMHub profile for: BASTARD. LONDON.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Senators attack Novartis over 'unconscionable' handling of Zolgensma data
- Boris Johnson announces fast-track immigration plans for top scientists
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- Blended Intelligence
- Planning a pharma exhibition stand? You must read this!
- Leaked no-deal Brexit document forecasts widespread shortages
- AbbVie scores FDA approval for arthritis treatment upadacitinib
- Novo Nordisk shareholder revolt reaches Europe
- BMS buoyed by FDA approval of Celgene’s myelofibrosis drug
PMHub
VCCP Health
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...
Latest intelligence
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
Quick links
Infographics
